|| Checking for direct PDF access through Ovid
The aim of the study was to evaluate the efficacy of hylan G-F 20 (Synvisc) in the treatment osteoarthritis (OA) of the hip joint.Twenty-seven patients (32 hips) with hip joint OA were enrolled in an open-label, prospective study. Demographics included 11 men and 16 women, 12 of whom had mild to moderate OA and 15 of whom had severe hip OA according to the Kellgren–Lawrence radiological grading system. Ultrasound-guided hyaluronic acid was administered to the affected hip from the lateral aspect of the joint at 1 week intervals, with a total of 3 treatments. The clinical assessment included visual analogue scale (VAS), Lequesne functional index, global patient assessment, Short-form 36 (SF-36), and use of paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs). All patients were evaluated at preinjection and at 2, 6, 12 weeks.When compared with the preinjection values, there was a statistically significant reduction in the VAS and Lequesne index at 6 and 12 weeks. There was also clear improvement in the quality of life score at the end of the 12 weeks. The percentages of paracetamol or NSAIDs use decreased to 25.9%. Adverse reactions were observed in nine patients after the injection.